Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Affiliations

Comment

Elif Hindié. J Clin Oncol. 2023.

. 2023 Aug 1;41(22):3873-3874.

doi: 10.1200/JCO.23.00686. Epub 2023 May 31.

¹ Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France.

No abstract available

Comment in

Reply to E. Hindié.
McManus HD, Armstrong AJ. McManus HD, et al. J Clin Oncol. 2023 Aug 1;41(22):3874-3875. doi: 10.1200/JCO.23.00794. Epub 2023 May 31. J Clin Oncol. 2023. PMID: 37257141 No abstract available.

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, Shore N, Kopyltsov E, Kalebasty AR, Bögemann M, Ye D, Cruz F, Suzuki H, Kapur S, Srinivasan S, Verholen F, Kuss I, Joensuu H, Smith MR. Hussain M, et al. J Clin Oncol. 2023 Jul 10;41(20):3595-3607. doi: 10.1200/JCO.23.00041. Epub 2023 Feb 16. J Clin Oncol. 2023. PMID: 36795843 Clinical Trial.